Back to Authors

Come, Steven E.

https://orcid.org/0000-0001-8136-2908

Mayo Clinic

Beth Israel Deaconess Medical Center

Citations 67

Post-traumatic stress disorder in young breast cancer survivors.
Vazquez, Danny Alberto, Rosenberg, Shoshana M. , Gelber, Shari , Ruddy, Kathryn J. , Morgan, Evan , Come, Steven E. , Schapira, Lidia , Vazquez, Danny, Recklitis, Christopher J. , Partridge, Ann H.

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 3_suppl | Pages: 202-202

10.1200/jco.2016.34.3_suppl.202 Get It

202 Background: Posttraumatic stress disorder (PTSD) is associated with morbidity and mortality in affected populations. Cancer survivors experience PTSD at a rate higher than the general population, with young age and female gender identified as risk factors. While young women with breast cancer experience greater psychosocial distress in general following diagnosis (dx), little is known about PTSD in this population. Methods: Women dx’d with Stage I-III breast cancer at age ≤ 40 were surveyed as a part of a multi-site cohort study. Demographic, treatment, psychosocial characteristics (including self-reported psychiatric conditions and use of psychiatric medications prior to dx), anxiety and depression (Hospital Anxiety and Depression Scale), fear of recurrence (Lasry Scale), and social support (Medical Outcomes Study) were assessed within 1 year after dx. PTSD was measured at 30 months post-dx using the PTSD Checklist – Civilian Version; a score ≥ 50 was considered positive for PTSD. Univariable and stepwise multivariable logistic regression were used to evaluate factors associated with PTSD. Results: 572 women were eligible for this analysis; median age at dx was 37 (range: 17-40); 87% had Stage I or II cancer. 37/572 women (6.5%) met criteria for PTSD at 30 months. Lower educational attainment, less financial comfort, less social support, stage 2 (vs. 1) disease, receipt of chemotherapy, fear of recurrence, anxiety and depression, and psychiatric comorbidities were associated (p ≤ 0.05) with PTSD in univariable analyses. Chemotherapy (OR = 3.48, 95% CI = 1.09-11.06), anxiety by HADS (OR = 20.29, 95% CI = 7.83-52.53), and psychiatric comorbidities (OR = 4.22, 95% CI = 1.40-12.74) were associated with increased likelihood of PTSD, whereas college education (OR = 0.25, 95% CI = 0.10-0.59) and greater social support (OR = 0.41, 95% CI = 0.17-0.99) appeared to be protective in multivariable analyses. Conclusions: PTSD affects a minority of young breast cancer survivors, with the prevalence in our cohort similar to that seen in other breast cancer populations. Early identification of those at risk for developing PTSD is essential for the adequate treatment of affected women and for the improvement of health outcomes and quality of life in cancer survivors.
BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Larsen, Bryce G., Tamimi, Rulla M. , Borges, Virginia F. , Garber, Judy E. , Partridge, Ann H.

JAMA Oncology | February 11, 2016 | Volume: 2 | Issue: 6 | Pages: 730

10.1001/jamaoncol.2015.5941 Get It

Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women
Collins, Laura C. , Gelber, Shari , Marotti, Jonathan D. , Ruddy, Kathryn J. , Brachtel, Elena F. , Schapira, Lidia , Come, Steven E. , Wensley, Taylor, White, Sarah, Borges, Virginia F. , Schedin, Pepper , Tamimi, Rulla M. , White, Sarah Ann , Warner, Ellen , Winer, Eric P. , Partridge, Ann H.

The Oncologist | May 30, 2015 | Volume: 20 | Issue: 7 | Pages: 713-718

10.1634/theoncologist.2014-0412 Get It

Abstract Background. The increase in breast cancer risk during pregnancy and postpartum is well known; however, the molecular phenotype of breast cancers occurring shortly after pregnancy has not been well studied. Given this, we investigated whether nulliparity and the time interval since pregnancy among parous women affects the breast cancer phenotype in young women. Materials and Methods. We examined molecular phenotype in relation to time since pregnancy in a prospective cohort of 707 young women (aged ≤40 years) with breast cancer. Parity was ascertained from study questionnaires. Using tumor histologic grade on central review and biomarker expression, cancers were categorized as luminal A- or B-like, HER2 enriched, and triple negative. Results. Overall, 32% were luminal A-like, 41% were luminal B-like, 9% were HER2 enriched, and 18% were triple negative. Although, numerically, patients diagnosed >5 years after pregnancy had more luminal A-like subtypes than women with shorter intervals since pregnancy, there was no evidence of a relationship between these intervals and molecular subtypes once family history of breast cancer and age at diagnosis were considered. Conclusion. Distribution of breast cancer molecular phenotype did not differ significantly among young women by parity or time interval since parturition when important predictors of tumor phenotype such as age and family history were considered. Implications for Practice: Distribution of breast cancer molecular phenotype did not differ among parous young women by time interval since pregnancy. The implication of these findings for clinical practice suggests that pregnancy-associated breast cancers may be seen up to 5 years beyond parturition.
Abstract P2-10-03: Decision-making surrounding adjuvant chemotherapy in young women with early stage breast cancer
Rosenberg, Shoshana M. , Sepucha, Karen , Ruddy, Kathryn J. , Schapira, Lidia , Come, Steven E. , Morgan, Evan , Gelber, Shari , Borges, Virginia F. , Lin, Nancy U. , Tamimi, Rulla M. , Partridge, Ann H.

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: P2-10-03-P2-10-03

10.1158/1538-7445.sabcs14-p2-10-03 Get It

Abstract Background: There is an increasing recognition that many young women with breast cancer will have favorable outcomes without chemotherapy. We sought to characterize decision-making surrounding adjuvant chemotherapy treatment (CT) in this population for whom chemotherapy has historically been a standard of care. Methods: As part of an ongoing, multi-center, prospective cohort of young women diagnosed with breast cancer at age 40 and younger, we identified 657 women with Stage I-III breast cancer. Participants were asked to complete surveys by mail that included questions about socio-demographics, decision-making, and treatment history within the first year following diagnosis. Tumor characteristics were ascertained via pathology and medical record review. We used Chi-square tests to compare: decisional involvement (patient-driven vs. shared vs. physician-driven), degree of confidence, and feeling informed about the CT decision (the latter two measured on a 0-10 scale, categorized as follows: 0-5=low; moderate=6-8; 9-10=high) between women who did and did not receive CT. To explore clinical appropriateness of the CT decision, we used logistic regression to assess the relationship between tumor characteristics and non-receipt of CT among women with Stage I/II disease. Results: Among women with Stage I (n=250), II (n=312), and III (n=95), disease, 66%, 95%, and 100%, received CT, respectively. A greater proportion of women who had CT were highly confident with their decision compared with women who did not have CT (80% vs. 60%, p<0.0001); women who did not have CT were more likely to report a low level of feeling informed about the CT decision compared to women who received CT (20% vs. 5%, p<0.0001). Women who did not have CT were also more likely to report the final CT decision as made by their doctor (49% vs. 28%) and less likely to report a shared decision (33% vs. 59%, p<0.0001). Non-receipt of CT in women with Stage I/II disease (n=546) was associated within having node negative disease, T1 (vs. T2 or larger), Her2- negative, and hormone receptor positive tumors. Conclusion: Although non-receipt of CT would be expected to be viewed favorably by patients and doctors, we found that women who received CT felt more confident and better informed than those who received no CT. Given that women who did not have CT were also less likely to perceive the CT decision as shared, improved communication together with better decisional support may be beneficial, especially for women who do not receive adjuvant chemotherapy. Citation Format: Shoshana M Rosenberg, Karen Sepucha, Kathryn J Ruddy, Lidia Schapira, Steven Come, Virginia Borges, Evan Morgan, Nancy U Lin, Shari Gelber, Rulla M Tamimi, Ann H Partridge. Decision-making surrounding adjuvant chemotherapy in young women with early stage breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-10-03.
Partner support and anxiety in young women with breast cancer
Borstelmann, Nancy A. , Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Morgan, Evan , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Psycho-Oncology | March 13, 2015 | Volume: 24 | Issue: 12 | Pages: 1679-1685

10.1002/pon.3780 Get It

AbstractObjectiveUsing a large prospective cohort of women age 40 or younger diagnosed with breast cancer, we examined the relationship between perceived partner support and anxiety.MethodsSix hundred seventy‐five young women with breast cancer Stages I–III, median age 36, completed a self‐report baseline questionnaire. Perceived partner support was assessed using items extracted from the marital subscale of the Cancer Rehabilitation Evaluation System; generalized social support was assessed with the Medical Outcomes Study–Social Support Survey. Anxiety was measured using the anxiety subscale of the Hospital Anxiety and Depression Scale. Multivariable logistic regression analyses evaluated the association between partner support, other sociodemographic factors, and anxiety.ResultsMean age at diagnosis was 35.4 years. Fourteen percent of the women were not partnered, and among those who were partnered or in a significant relationship, 20% were categorized as unsupported. In univariate and multivariable analysis adjusting for sociodemographic factors, women in an unsupported‐partnered relationship had higher odds of anxiety symptoms compared with women in a supported‐partnered relationship. Young age and being financially insecure were also both independently associated with anxiety.ConclusionsOur findings suggest that partner support may play a key role in a young woman's adjustment to a serious stressor such as breast cancer. In addition, younger age increases vulnerability to anxiety as does struggling with finances. Because supportive efforts of a partner have potential to protect against the impact of stress, interventions to enhance partner support and reduce anxiety might be beneficial to address challenges experienced as a couple in this setting. Copyright © 2015 John Wiley & Sons, Ltd.
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Brown, Myles , Kumar, Rakesh , Johnston, Stephen, Paik, Soonmyung , Hart, Carol S. , Ingle, James N. , Dowsett, Mitch , Hilsenbeck, Susan Galloway , Lee, Adrian V. , Pritchard, Kathleen I. , Winer, Eric P. , Brown, Myles

Clinical Cancer Research | March 21, 2006 | Volume: 12 | Issue: 3 | Pages: 997s-1000s

10.1158/1078-0432.ccr-05-2268 Get It

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Bissell, Mina J. , Brown, Myles , Goss, Paul E. , Green, Jeffrey E., Medina, Daniel , Nicholson, Robert I., Santen, Richard J. , Hart, Carol S. , Ellis, Matthew J. , Ingle, James N. , Lee, Adrian V. , Schiff, Rachel , Brown, Myles

Clinical Cancer Research | September 21, 2005 | Volume: 10 | Issue: 1 | Pages: 327s-330s

10.1158/1078-0432.ccr-031213 Get It